Compare Maravai LifeSciences Holdings Inc. Class A Common Stock (MRVI) vs Vanguard S&P 500 ETF (VOO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Maravai LifeSciences Holdings Inc. Class A Common Stock vs Vanguard S&P 500 ETF — how do they compare? Maravai LifeSciences Holdings Inc. Class A Common Stock trades at $6.56 (market cap $972.90M), while Vanguard S&P 500 ETF trades at $704.55 (market cap $1.80T). The key difference: Vanguard S&P 500 ETF is far larger — about 1850.1× Maravai LifeSciences Holdings Inc. Class A Common Stock's market cap, and Vanguard S&P 500 ETF is trading nearer its 52-week high, Maravai LifeSciences Holdings Inc. Class A Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Maravai LifeSciences Holdings Inc. Class A Common Stock for 0 Days and Vanguard S&P 500 ETF for 57 Days on average.
| MRVI | VOO | |
|---|---|---|
Market Cap | $972.90M | $1.80T |
Volume | 4,325,710 | 4,954,490 |
Sector | Health | Broad Market / Factor |
52-Week High | $9.00 | $716.17 |
52-Week Low | $2.83 | $580.93 |
Typical Hold Time | 0 Days | 57 Days |
Enterprise Value | $1.08B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Maravai LifeSciences (MRVI) trades at $6.53, down 7.51% in the last session amid mixed signals. The stock shows improving fundamentals with Q2 2026 revenue growth of 9% and three consecutive earnings beats, though it remains unprofitable with a -37.07% net margin. Technical analysis indicates neutral positioning with key support at $6 and resistance at $7. Recent news highlights patent expansions in China and institutional accumulation.
The outlook remains cautiously optimistic with analyst consensus pointing to 7% upside potential to the $7.00 price target. Key opportunities include margin expansion and RNA technology leadership, while risks center on persistent cash burn and competitive pressures in life sciences. The stock offers speculative growth potential for risk-tolerant investors.
VOO trades at $715.14 with minimal daily movement, showing strong technical momentum with bullish moving averages. The ETF maintains its position as a core S&P 500 holding with upcoming dividend distribution. Recent news highlights its role in long-term wealth building and recession resilience, though short interest increased 46.9% in September.
VOO offers diversified exposure to large-cap US equities with low expense ratio advantages. Key risks include market-wide volatility and potential earnings growth slowdown from 35% to 15% in 2027. The ETF remains a foundational holding for long-term investors despite near-term valuation concerns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Maravai LifeSciences Holdings Inc. Class A Common Stock
Maravai LifeSciences Holdings Inc. is a life sciences company supporting drug therapy, diagnostic, and vaccine development through four operating brands: TriLink BioTechnologies (nucleic acid and mRNA synthesis), Cygnus Technologies (biologics safety testing), Glen Research (oligonucleotide synthesis materials), and Alphazyme (enzyme manufacturing). It serves biotech and biopharma customers from discovery through commercial manufacturing.
Read more on MRVI →About Vanguard S&P 500 ETF
VOO is a foundational ETF that tracks the S&P 500 Index, providing exposure to 500 of the largest and most established companies in the United States. Renowned for its ultra-low expense ratio and tax efficiency, it serves as a core building block for long-term investors seeking to capture the total return of the U.S. large-cap market in a single, highly liquid vehicle.
Read more on VOO →
